🟢 FDA approves Axsome Therapeutics’ Auvelity for Alzheimer’s agitation: Axsome said up to 76% of patients with Alzheimer’s disease have agitation, which is characterized by pacing, restlessness and verbal or physical …
Moderna in talks with FDA over Phase 4 Covid vaccine data
Moderna said it’s working with US regulators to provide post-marketing data on its Covid-19 vaccines that could restore their use to a wider group after


